Sequential therapy a winner in osteoporosis

The administration of abaloparatide (Tymlos) for 18 months followed by alendronate (Fosamax) for 2 years was associated with dramatic reductions in fracture risk among postmenopausal women, according to research presented at the American Society for Bone and Mineral Research annual meeting.Medpage Today
Source: Society for Endocrinology - Category: Endocrinology Source Type: news